A pill called upadacitinib, already approved for treating rheumatoid arthritis, might also ease another common immunological condition — eczema. In two phase 3 clinical trials, patients with moderate to severe eczema showed rapid and significant improvements after taking the drug, said researchers at Mount Sinai in New York City. The clinical trials were funded by… read on > read on >







